Weekly Topotecan Therapy in Patients With Ovarian Cancer

Stopped early · Phase 2

Conditions studied: Ovarian Cancer

In brief

The purpose of this study is to find out the safety and feasibility of weekly topotecan consolidation therapy in patients with ovarian cancer.

Key facts

Study ID

NCT00194935

Run by

Weill Medical College of Cornell University

People needed

32

Starts

2003-02-01

Expected to finish

2006-08-01

Last updated by the study team

2006-09-13

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have a histopathologic diagnosis of epithelial ovarian cancer.
• Patients must have completed front-line chemotherapy and be clinically NED (CA 125 <35, negative CT scan, negative physical exam).
• Patients may have a second look laparoscopy, however, there must be no gross disease present (microscopic disease or pathologically negative).
• Patients must not have had other myelosuppressive therapy within four weeks of initiating topotecan therapy.
• Topotecan treatment must begin within 10 weeks following last cycle of initial chemotherapy.
• Patients may have had only one prior chemotherapy regimen.

You may not qualify if…

• Patients with a concomitant malignancy other than squamous cell or basal cell skin cancer.
• Patients who are pregnant or breast-feeding.

Where it is running

• Weill Medcial College of Cornell University — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.